期刊论文详细信息
European Medical Journal Hematology
Exploring a Role for Mitapivat in Children with Pyruvate Kinase Deficiency
article
Rachael Grace1 
[1] Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School
DOI  :  10.33590/emjhematol/10057650
来源: European Medical Journal
PDF
【 摘 要 】

Three posters presented at the European Hematology Association (EHA)2022 Hybrid Congress focused on the role of mitapivat in the treatmentof pyruvate kinase (PK) deficiency, a rare inherited chronic haemolytic anaemia.1-3Mitapivat is a first-in-class, oral, allosteric activator of the red blood cell (RBC) PKenzyme, and treats the underlying pathophysiology of PK deficiency.1-3 Results froma long-term extension study in adults have confirmed the consistency and durabilityof treatment response achieved with mitapivat, providing the basis for its ongoingevaluation in the treatment of paediatric patients with PK deficiency.1 Currently,there are no approved pharmacotherapies that target the underlying cause ofhaemolytic anaemia in children with PK deficiency. To address this global unmetneed, recruitment is currently underway into two international Phase III paediatricstudies (ACTIVATE-KidsT [NCT05144256]4 and ACTIVATE-Kids [NCT05175105]5),which will evaluate efficacy and safety of mitapivat treatment in children with PKdeficiency who are regularly transfused and not regularly transfused, respectively.

【 授权许可】

CC BY-NC   

【 预 览 】
附件列表
Files Size Format View
RO202302050000132ZK.pdf 1310KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:0次